Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2021 Jan 15;11:1523. doi: 10.1038/s41598-021-81104-y

Mycobacterium tuberculosis Rv3160c is a TetR-like transcriptional repressor that regulates expression of the putative oxygenase Rv3161c

Hasan Tükenmez 1,2,3,4,, Souvik Sarkar 1,3, Saber Anoosheh 1,3, Anastasiia Kruchanova 2,3, Isabel Edström 2,3, Gregory A Harrison 5, Christina L Stallings 5, Fredrik Almqvist 1,3, Christer Larsson 2,3,6,
PMCID: PMC7810876  PMID: 33452380

Abstract

Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is a major health threat listed among the top 10 causes of death worldwide. Treatment of multidrug-resistant Mtb requires use of additional second-line drugs that prolong the treatment process and result in higher death rates. Our team previously identified a 2-pyridone molecule (C10) that blocks tolerance to the first-line drug isoniazid at C10 concentrations that do not inhibit bacterial growth. Here, we discovered that the genes rv3160c and rv3161c are highly induced by C10, which led us to investigate them as potential targets. We show that Rv3160c acts as a TetR-like transcriptional repressor binding to a palindromic sequence located in the rv3161c promoter. We also demonstrate that C10 interacts with Rv3160c, inhibiting its binding to DNA. We deleted the rv3161c gene, coding for a putative oxygenase, to investigate its role in drug and stress sensitivity as well as C10 activity. This Δrv3161c strain was more tolerant to isoniazid and lysozyme than wild type Mtb. However, this tolerance could still be blocked by C10, suggesting that C10 functions independently of Rv3161c to influence isoniazid and lysozyme sensitivity.

Subject terms: Tuberculosis, Target identification, Target validation, Gene regulation

Introduction

Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is still a major infectious disease worldwide1. In 2018, an estimated 10 million people fell ill with TB and 1.5 million died globally1. The fight against TB is exacerbated by the emergence of multidrug-resistant strains (MDR-TB) resistant to at least two of the first-line drugs to treat TB, isoniazid (INH) and rifampicin1. These infections require additional second-line drugs and longer duration of treatment where the treatment success rate drops substantially1. Over the last 50 years, only three new TB drugs have been developed and approved for use against TB: bedaquiline, delamanid and most recently, pretomanid. However, there are already several cases reported with TB resistant to both bedaquiline and delamanid25. Therefore, there is still a desperate need to develop new strategies to target drug-resistant Mtb.

Previously, our team described a thiazolo ring-fused 2-pyridone (C10) with the ability to increase sensitivity to oxidative stress, acid stress and the first-line antibiotic INH6. C10 was found to potentiate the bactericidal activity of INH and prevent the occurrence of INH-resistant mutants6. Moreover, INH-resistant katG mutants were re-sensitized to INH in the presence of C10, demonstrating that INH resistance can be circumvented6. We also showed that C10 inhibited respiration in Mtb, and previous reports have shown that both inhibition and stimulation of Mtb respiration can potentiate bactericidal activity of INH7,8. However, the link between C10 effects on respiration and C10 effects on INH sensitivity were not elucidated. The C10 target(s) in Mtb as well as molecular mechanism of the INH potentiation is unknown.

Here, we discovered the rv3160c-rv3161c operon to be induced by C10 in Mtb. We found that C10 inhibits DNA-binding activity of Rv3160c, a putative TetR-like transcription factor, and results in increased expression of Rv3161c, a protein of unknown function related to oxygenases found in other bacteria. When knocked out, Δrv3161c mutants became more tolerant to both INH and lysozyme, indicating that the Rv3161c plays an active role in both INH potentiation and maintenance of cell wall integrity. However, the Δrv3161c mutants can still be sensitized to both INH and lysozyme by C10, excluding the potential involvement of rv3160c-rv3161c in the C10 effect.

Results

Expression of the rv3160c-rv3161c operon is upregulated in response to C10

In our previous study, the small molecule C10 was discovered to reduce tolerance to oxidative stress, acid stress and to the first line antibiotic INH in Mtb6. Furthermore, C10 could restore INH sensitivity in otherwise INH-resistant katG mutants6. C10 also perturbed respiratory homeostasis, but its mechanism of action is unclear6.

In order to identify the target(s) of C10 and discover the mechanism behind its INH potentiation, we re-visited our previous RNA-seq data and looked closer at the top genes induced by C10. The rv3160c and rv3161c genes, positioned within a proposed two-gene operon9,10, were among the top 5 genes upregulated by C10 under hypoxic growth conditions (13-fold and 12-fold, respectively)6. These genes particularly caught our attention, as they have been shown to be induced by triclosan, an antibacterial that inhibits InhA, resulting in deficient mycolic acid synthesis in Mtb, similar to INH11,12.

According to the RNA-seq results, upregulation of the rv3160c-rv3161c operon by C10 was observed under hypoxic growth conditions but not under aerated conditions. To investigate this further, we performed quantitative real-time PCR (qRT-PCR) analysis of the rv3160c-rv3161c operon in response to C10 molecule under aerobic conditions. To improve solubility of C10, we used a C10-imidazole salt (C10-IMD) instead of C10 during this study (Fig. S1)6. qRT-PCR data showed that expression of the rv3160c-rv3161c operon increases 102 ± 32-fold under aerated growth conditions upon exposure to 25 µM C10-IMD for 48 h (Fig. 1). Furthermore, expression of this operon was induced even further, 1035 ± 571-fold upon exposure to a combination of 25 µM C10-IMD and 0.1 µg/ml INH for 48 h (Fig. 1). There were no significant changes in expression of the operon upon exposure to either 0.1 µg/ml INH or 25 µM IMD alone for 48 h (Fig. 1). These findings suggest that INH and C10-IMD have a synergistic role in the induction of the rv3160c-rv3161c operon. Based on this, we decided to investigate the rv3160c-rv3161c operon further.

Figure 1.

Figure 1

Expression of the rv3160c-rv3161c operon is significantly induced by C10-IMD. Mtb Erdman WT was cultivated in Sauton’s medium at 37 °C until its OD600 reached 0.3. The cells were then exposed to 0.1% DMSO, 0.1 µg/ml INH and 25 µM C10-IMD separately or in combination for 48 h at 37 °C. Differences in expression of the rv3160c-rv3161c operon were determined by qRT-PCR analysis performed by targeting rv3161c coding region. Expression of the sigA gene was determined by qRT-PCR analysis and used as housekeeping control. Relative fold-change in rv3160c-rv3161c operon expression was calculated for each biological replicate by the Livak (2−ΔΔCt) method. Bar graphs were plotted based on average and standard deviation obtained from three independent biological replicates and statistical analysis comparing to the DMSO control was determined by one-tail t-test that was performed using GraphPad Prism version 8.4.3 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com (**p < 0.01).

Rv3160c is a TetR-like transcription repressor of the rv3160c-rv3161c operon

The rv3160c gene encodes a putative TetR family transcriptional regulator (TFTR) and is uniquely found in mycobacteria causing TB13. Mycobacterial genomes are highly enriched with several TFTRs, of which the majority act as repressors of gene expression13. Even though Rv3160c has been suggested to be a TFTR based on sequence domain similarities to other TFTRs, its function and possible target(s) have not been described. The majority of the TetR-like transcriptional repressors are known to regulate their neighboring genes and often to be co-transcribed with their regulatory targets13. Several previous studies have suggested that the rv3160c and the rv3161c genes are located within the same operon based on their correlated gene expression in response to various environmental factors11,1419. However, a genome wide study suggested the rv3160c gene to have its own independent transcriptional start site (TSS) starting at 406 bp upstream of the rv3160c open reading frame (ORF), overlapping with the rv3161c ORF20. To determine which promoter region was responsible for the transcription of rv3160c in our conditions, we measured the expression levels of the rv3160c gene while targeting the region between the rv3160c-rv3161c operon TSS and the recently proposed independent TSS of the rv3160c gene with a CRISPRi construct (Fig. S2). We found that the expression of the rv3160c gene was significantly reduced suggesting that rv3160c is mainly co-transcribed with the rv3161c gene (Fig. S2). However, the existence of additional TSSs, perhaps of importance in response to other conditions, cannot be excluded based on this data.

We designed an experiment to test whether expression of the neighboring rv3161c gene was regulated by Rv3160c (Fig. 2A). We reduced expression of rv3160c gene (~ threefold) by rv3160c-CRISPRi (Fig. 2B), which resulted in a 33 ± 3-fold increased expression of the rv3161c gene (Fig. 2C). This data shows that decreasing rv3160c expression results in an increase in rv3161c expression, although it does not show whether this occurs through direct regulation or not.

Figure 2.

Figure 2

Rv3160c acts as transcriptional repressor of the rv3160c-rv3161c operon. (A) Schematic representation of the rv3160c-rv3161c operon and the relative positions of the targets for CRISPRi and qRT-PCR. (B,C) qRT-PCR analysis of rv3160c and rv3161c mRNA expression in Mtb Erdman WT strain harboring either vector control (pJR965) or the rv3160c-CRISPRi (pSA253) construct in absence (−) or presence (+) of 100 ng/ml aTc. sigA mRNA expression was used as control and relative fold change in rv3160c and rv3161c mRNA expression were calculated for each biological replicate by the Livak (2−ΔΔCt) method. Average value of 3 technical replicates was used for each biological replicate. Bar graphs were plotted based on average and standard deviation obtained from three independent biological replicates and statistical analysis was determined by one-tail t-test that was performed using GraphPad Prism version 8.4.3 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com (*p < 0.05, **p < 0.01).

TFTRs typically bind to palindromic motifs as dimers, thus we searched for such motifs in the upstream sequence of the rv3160c-rv3161c operon. We identified a stretch of 50 bp containing 12-bp and 8-bp inverted repeats starting at the − 29 bp upstream of the operon (Fig. 3A). We confirmed that Rv3160c binds to a 142 bp DNA fragment containing these palindromic motifs, resulting in a DNA shift using the electrophoretic mobility shift assay (EMSA) (Fig. S3). We then digested the 142 bp DNA fragment with different restriction enzymes to narrow down the region that is targeted by Rv3160c (Fig. S3). We found that that presence of both inverted repeats as well as the − 10 region were necessary for an efficient interaction, thus we decided to use 86 bp DNA fragment containing both these palindromic motifs for the remaining EMSAs (Fig. 3B). The binding of Rv3160c to these palindromes would block access of the RNAP to the − 10 sigma factor binding site and repress transcription of the rv3161c. To test if the palindromic motifs were important for Rv3160c binding, we performed EMSAs with modified DNA fragments. We used a higher concentration of Rv3160c (100 pmol) in these assays compared to those presented in Fig. 3 (10 pmol) to ensure the protein was in excess to detect lower affinity binding events. In these experiments, we observed that our DNA dye bound to purified Rv3160c (Fig. S4), obscuring the shifted DNA band. Nevertheless, this interaction would not interfere with the migration of the band in the acrylamide gels as staining took place after the gel runs were completed. We evaluated Rv3160c binding by quantifying the amount of unbound DNA in the presence of Rv3160c as a percentage of the unbound DNA in the absence of Rv3160c for each DNA construct. To test if the inner palindrome is important for Rv3160c binding, we shuffled the 8 bp inverted repeats in the inner palindrome, without eliminating the palindrome structure or base composition (Fig. S5A). Rv3160c showed decreased binding to the fragment harboring a shuffled inner palindrome, leaving 83% of the DNA unbound, as compared to the unmodified fragment, where only 8% of the DNA remains unbound by Rv3160c (Fig. S5B). We then incubated Rv3160c with DNA fragments harboring a shuffled outer palindrome or harboring both shuffled inner and outer palindromes and found that nearly all of the DNA remained unbound in the presence of Rv3160c (Fig. S5). Furthermore, by modifying the two non-matching nucleotides located between the inner and outer palindromes to create a single 21 bp inverted repeat, we found that Rv3160c was still able to bind most of the DNA fragment, leaving 37% of the DNA unbound (Fig. S5A). These findings demonstrate that the ability of Rv3160c to bind the sequence upstream of rv3161c is dependent on the sequence of both inverted repeats.

Figure 3.

Figure 3

Binding of Rv3160c to the rv3160c-rv3161c operon is blocked by C10-IMD. (A) Schematic depicting model of the Rv3160c dimer binding to the palindromic sequence present in the rv3161c upstream fragment. (B) EMSA assay using an 86 bp rv3161c upstream fragment (1 pmol; lanes 1–3) and a 204 bp cfp10 upstream fragment as negative control fragment (1 pmol; lanes 4–5). Lane 1 and 5: no protein added. Lanes 2, 3 and 5: binding reaction with 10 pmol Rv3160c. Lane 3: 50 nmol C10-IMD. DNA Ladder: Thermo Scientific GeneRuler 1 kb Plus (SM1331).

C10-IMD inhibits the interaction between Rv3160c and the rv3161c upstream target sequence

As mentioned above, expression of the rv3160c-rv3161c operon is induced by C10-IMD. Thus, we hypothesized that C10-IMD might interfere with Rv3160c function. Indeed, we found that Rv3160c was no longer capable of interacting with the sequence upstream of rv3161c in the presence of C10-IMD in the EMSA (Fig. 3B). To investigate whether C10-IMD interacted directly with Rv3160c, we analyzed the effect of C10-IMD on Rv3160c tryptophan fluorescence emission. There are 3 tryptophan residues available in Rv3160c and the binding interaction between C10-IMD and Rv3160c was studied using tryptophan fluorescence. The presumption is that if C10-IMD binds Rv3160c and some of the tryptophan residues are in close proximity to the C10-IMD binding site, compound binding might affect the intrinsic fluorescence of Rv3160c. Rv3160c was titrated with increasing concentrations of C10-IMD and relative fluorescence intensity was found to decrease in a concentration-dependent manner (Fig. 4A). The fluorescence quenching was further analyzed by Stern–Volmer equation (Eq. 1, see “Methods” section) to determine the Stern–Volmer quenching constant (Ksv) (Fig. 4B), which signifies the equilibrium binding constant for complex formation in the light-induced electronic excited state resulting in the quenching of intrinsic fluorescence of tryptophan. In this study, the Stern–Volmer plot analyzes the type of fluorescence quenching of tryptophan residues in Rv3160c by plotting relative emission intensity against C10-IMD concentration. In the case of Rv3160c, a tryptophan might be buried in the protein, whose fluorescence quenching depends on the microenvironment, solvent accessibility, and binding of C10-IMD. Overall, the tryptophan fluorescence quenching is a combined contribution of the microenvironment of all tryptophan residues in the presence of C10-IMD. If tryptophan residues are in close proximity of C10-IMD binding site, C10-IMD binding leads to fluorescence quenching of tryptophan while the fluorescence of other tryptophan residues that are not involved in C10-IMD binding would not be quenched. The Stern–Volmer plot, therefore, helps to understand the binding process leading to quenching phenomena21. To calculate the binding dissociation constant (KD) and the number of binding site (n), the logarithmic Eq. (2) (see “Methods” section) was used. The log(Kb) (Kb denotes binding association constant) value had been determined from the intercept of the plot, shown in Fig. 4C. The binding dissociation constant (KD) was found to be 44.51 ± 0.85 µM using Eq. (3). The number of binding sites for the C10-IMD in Rv3160c was found to be 0.94 ± 0.09 suggesting one binding site of C10-IMD in Rv3160c.

Figure 4.

Figure 4

C10-IMD binds to a single site in Rv3160c and the interaction does not cause changes in the secondary structure of the protein. (A) Fluorescence quenching spectra of Rv3160c. The 10 µM Rv3160c in PBS solution is excited and quenching of fluorescence is recorded in the presence of varying concentrations of C10-IMD (1–100 μM). (B) Stern–Volmer plot of decrease in mean fluorescence intensity of Rv3160c in the presence of varying concentrations of C10-IMD derived from three independent experiments. The dynamic quenching rate constant Ksv is evaluated from the slope of the line. (C) Logarithmic plot of mean relative fluorescence quenching of Rv3160c derived from three independent experiments against logarithmic concentrations of C10-IMD. KD is calculated from the intersection of the line with the y axis and the number of binding sites (n) from the slope of the line. (D) CD spectra of Rv3160c in the presence of 1 µM or 10 µM 86 bp rv3161c upstream fragment (DNA) (Fig. 2C). (E) CD spectra of Rv3160c in the presence of 10 µM or 100 µM C10-IMD. Error bars in (B) and (C) indicate standard deviation.

TFTRs usually consist of two domains: one signal-receiving and the other one DNA-binding. Interactions of TFTRs with their target DNAs often lead to structural changes, especially in the DNA-binding domain2225. Similarly, specific molecules can bind to the regulatory domain of TFTRs, resulting in conformational changes that make TFTRs incapable of binding their DNA targets26,27. According to our EMSA experiments, Rv3160c cannot bind to its DNA target upon addition of C10-IMD. Thus, we investigated whether interaction with C10-IMD results in conformational changes in Rv3160c using circular dichroism (CD) spectroscopy. We discovered that the ellipticity of Rv3160c was reduced upon addition of its DNA target, indicating changes in the secondary structure (Fig. 4D). In contrast, no change in the ellipticity of Rv3160c was observed in the presence of C10-IMD (Fig. 4E), indicating that C10-IMD did not alter the secondary structure of Rv3160c in the absence of DNA. There is a slight change in the ellipticity in the presence of C10-IMD approximately at 208 nm in Fig. 4E does not have much impact on overall secondary structure of Rv3160c.

Deletion of rv3161c results in increased sensitivity to INH and lysozyme

C10-IMD directly binds Rv3160c, a TetR-like transcriptional repressor, which could be leading to the increased expression of the rv3160c-rv3161c operon in the presence of C10-IMD. We hypothesized that INH potentiation by C10-IMD might be regulated through the cellular concentration of Rv3161c, a putative oxygenase. To test this, we used recombineering to generate a rv3161c knock-out strain and tested its sensitivity to INH. Both wild type and Δrv3161c strains were incubated for 2 weeks at 37 °C with varying concentrations of INH in U-bottomed 96-well plates. After 2-weeks incubation, we scored the pellet formations in each well as a semi-quantitative indication of bacterial growth and spotted them on 7H10 plates followed by additional 3-weeks of incubation at 37 °C to assess the presence of viable bacteria. We discovered that the Δrv3161c strain was more resistant to INH in comparison to wild type, as it could survive up to double the INH concentration (0.016 µg/ml) (Fig. 5). We also observed that addition of 5 µM C10-IMD potentiated INH sensitivity in both wild type and Δrv3161c strains, demonstrating that the effect of C10-IMD on INH potentiation occurs independently of Rv3161c (Fig. 5).

Figure 5.

Figure 5

Deletion of the rv3161c gene results in higher resistance to isoniazid and lysozyme. (A) Representative images showing effect of INH and lysozyme on bacterial growth scored by pellet formation. Mtb Erdman WT and ∆rv3161c strains were incubated 2 weeks in Sauton’s medium with 0.02% DMSO or 5 µM C10-IMD in addition to various concentration of INH (left; 0.002–0.064 µg/ml) or lysozyme (right; 3.9–125 µg/ml). (B) Representative images showing effect of INH and lysozyme treatment on bacterial survival scored by spotting bacteria exposed to INH (left; 0.002–0.064 µg/ml) or lysozyme (right; 3.9–125 µg/ml) in the presence of 0.02% DMSO or 5 µM C10-IMD on antibiotic-free 7H10 plates.

Previous studies show that expression of the rv3160c-rv3161c operon is upregulated in the lipid-rich environments18 and upon treatment with cell wall synthesis inhibitors11,17,19, raising the question of whether these genes play a role in cell wall integrity. We set up a similar growth and survival assay to test the cell wall integrity of both wild type and Δrv3161c strains by incubating them in the presence of varying concentrations of lysozyme, an antimicrobial enzyme that cleaves the peptidoglycan component of the bacterial cell wall. The Δrv3161c strain survived exposure up to double the lysozyme concentration (62.5 µg/ml) compared to the wild type strain (Fig. 5). In addition, we found that both the wild type and Δrv3161c strains were more sensitive to lysozyme in the presence of 5 µM C10-IMD (Fig. 5).

Discussion

Expression of the rv3160c-rv3161c operon has been reported to be induced by various anti-microbial agents such as triclosan11,19, thioridazine16,17,19, SRI#96715, SRI#919015 and chlorpromazine19. Rv3161c encodes a putative oxygenase that shares high amino acid sequence identity (32–62%) with other Rieske oxygenases found in several organisms. Rieske oxygenases are known to be involved in the degradation of arenes, therefore it has been suggested that Rv3161c might hydroxylate the benzene ring structures found in these anti-microbial agents resulting in detoxification11,15,17. However, neither deletion nor overexpression of the rv3161c gene influenced the minimal inhibitory concentration (MIC) of triclosan or other anti-microbial agents28. Therefore, upregulation of rv3161c expression was suggested to be a failed attempt of the bacteria to counteract these drugs28. In another study, mutations in the rv3161c gene were found to cause resistance against the 2,4-diaminoquinazoline (DAQ) anti-tubercular agent and Rv3161c was proposed to convert pro-drug DAQ into its active form29. Despite all of these previous studies, the mechanism of action of the Rv3161c in response to antimicrobial agents is still unclear.

We discovered that rv3161c is highly expressed in response to the C10-IMD compound that previously has been shown to potentiate INH sensitivity6. Induced rv3161c expression was also observed as a response to 2-aminoimidazoles (2-AI), a class of molecules that potentiate sensitivity to β-lactam antibiotics by increasing cell permeability14. Several studies have suggested that Rv3161c is involved in lipid metabolism and cell wall biogenesis11,1719. In this study, we found that Δrv3161c mutants become more resistant to INH as well as lysozyme, an enzyme degrading the peptidoglycan layer of the cell wall (Fig. 5). We hypothesize that elevated Rv3161c may disturb the cell wall integrity and increase cell permeability, resulting in increased INH and lysozyme sensitivity. The Δrv3161c mutants can still be sensitized against both INH and lysozyme by C10-IMD, demonstrating that C10-IMD functions independent of Rv3161c to elicit these effects (Fig. 5). We tried to generate a Δrv3160c mutant to test whether elevated Rv3161c in the absence of C10-IMD could increase sensitivity against INH and lysozyme, however we failed to generate such a mutant in several attempts.

In this study, we clarified the function of Rv3160c as a TetR-like transcriptional repressor that regulates rv3161c expression. Despite the fact that several publications have suggested the rv3160c-rv3161c operon to be involved in key processes such as drug detoxification, lipid metabolism and cell wall biogenesis11,1419,29, the function of the Rv3161c remains unknown. Further investigation aiming to elucidate the function of Rv3161c will lead to important insights into Mtb biology.

Methods

Bacterial strains and growth conditions

WT E. coli DH5α was grown in Luria Broth (Difco) as shaking cultures at 37 °C and kanamycin at 50 µg/ml was used for selection when required.

WT Mtb Erdman and the rv3161c knockout with Mtb Erdman background were grown in either Middlebrook 7H9 medium (BD Difco) supplemented with 0.05–0.1% Tween80 and 10% ADS (0.5% albumin, 0.2% dextrose and 0.085% saline) or Sauton’s medium [0.0005% (w/v) KH2PO4, 0.0005% (w/v) MgSO4, 0.004% (w/v) l-asparagine, 0.06% glycerol, 0.00005% (w/v) ferric ammonium citrate, 0.002% (w/v) citric acid, 0.0001% ZnSO4, pH 7] supplemented with 0.1% Tween80 as liquid shaking cultures at 37 °C. These strains were also grown on Middlebrook 7H10 solid medium (Remel) supplemented with 0.05% Tween80, 0.2–0.5% Glycerol and 10% ADS at 37 °C. Kanamycin at 20 µg/ml and anhydrotetracycline (aTc) at 100 ng/ml were used when required. All the strains used in this work are listed in Table S1.

Construction of rv3160c-CRISPRi and rv3161c-CRISPRi strains

To investigate regulation of the rv3160c-rv3161c operon, we silenced expression of the rv3160c and the rv3161c genes individually by using the dCas9Sth1 CRISPRi system30. This system utilizes a catalytically inactivated CRISPR1 cas9 allele and provides an RNA-guided platform for sequence-specific control of gene expression. The single guide RNAs (sgRNAs) for each gene were determined and ranked by PAM score. Forward and reverse oligonucleotides (Table S2) corresponding to the top-ranked sgRNA sequence for each gene were annealed together to form double stranded DNA fragments and subsequently cloned into the BsmBI site of pLJR965 as described before30. The resulting plasmids, named pSA253 (targeting rv3160c) and pSA256 (targeting rv3161c), were electroporated into Mtb Erdman to obtain TB3 and TB4 respectively.

RNA isolation and cDNA synthesis

Mtb Erdman strains harboring pLRT965 (empty vector), pSA253 (targeting rv3160c) or pSA256 (targeting rv3161c) were grown in 7H9 medium supplemented with 0.05% Tween80, 10% ADS and 20 µg/ml kanamycin until their optical density (OD600) reaches to 0.3 in the presence of aTc (100 ng/ml) to induce expression of gene-specific sgRNA. Same strains were also cultivated similarly but in the absence of aTc as non-induced controls. Equivalents of 6 OD600-unit cells were harvested by centrifugation and resuspended in 1 ml TRI Reagent (Invitrogen). Cell suspensions were transferred into screw-cap homogenizing tubes containing 0.4 ml of 0.1 mm Zirconia/Silica beads (BioSpec) and lysed in a bead beater 8 times for 30 s with a 1-min rest on ice between each cycle. After a centrifugation at 13,000 g for 45 s, supernatants were transferred into new tubes and mixed with 300 µl chloroform followed by incubation at room temperature for 2 min. The samples were centrifuged at 13,000 g for 5 min and aqueous phase were transferred into new tubes. An equal volume of absolute ethanol was mixed with each sample and subsequently transferred into RNeasy columns (Qiagen) followed by purification according to the manufacturer’s instruction. Isolated RNA samples were then DNase-treated with TURBO DNA-free kit (Invitrogen) to eliminate any genomic DNA contamination. cDNA was prepared using qScript cDNA Synthesis kit (Quantabio) according to the manufacturer’s instruction.

Quantitative real-time PCR

Expression levels of rv3160c and rv3161c genes were determined by qRT-PCR with cDNA equivalent to 50 ng RNA using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific) and the oligonucleotides listed in Table S3. RNA samples that were not reverse transcribed were used to confirm that there were no DNA contamination, and the integrity of the amplicons were confirmed by melting curves for each sample. All qRT-PCR experiments were performed with three technical replicates derived from three biological replicates. Signals were normalized to the housekeeping sigA mRNA and quantified by the Livak (2−ΔΔCt) method31. The Ct values of induced samples were compared to the corresponding Ct values of uninduced samples. Statistical analysis was performed using the one-tailed t-test and the results were plotted as bar graphs based on average and standard deviation obtained from three biological replicates by GraphPad Prism version 8.4.3 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com.

Electrophoretic mobility shift assay

EMSA was performed with 142 bp rv3161c upstream fragment (undigested or digested with BglI, HincII or TaqI), 86 bp rv3161c upstream fragment (wild type or altered) or 204 bp cfp10 upstream fragment. The 142 bp rv3161c upstream sequence was directly amplified from chromosomal DNA with BS3161F and BS3161R oligonucleotides. Complementary oligonucleotides bearing the 86 bp rv3161c upstream sequence (wild type or altered) were annealed and amplified with UniPal_F and UniPal_R oligonucleotides (Table S4). cfp10 upstream sequence was also directly amplified from chromosomal DNA with EMSA_CFP10-F and EMSA_CFP10-R oligonucleotides (Table S4). The binding reactions were prepared in 10 mM Tris–HCl (pH 8.0), 150 mM KCl, 0.5 mM EDTA (pH 8.0), 0.1% Triton-X 100, 12.5% glycerol, 0.2 mM DTT, 0.1 mg/ml BSA and 10 ng/ul Poly-dIdC in the presence of 1 or 4 pmol DNA targets, 10 or 56 pmol Rv3160c (produced by the Protein Expertise Platform at Umeå University in 1× PBS) and/or 50 nmol C10-IMD and incubated for 30 min at 37 °C. Reaction mixes were then loaded onto 6% polyacrylamide gels and run at 80 V in 0.5% TBE buffer for 75 min. The gels were then stained in 3× GelRed (Biotium) buffer for 15 min followed by washing with MQ water for 15 min twice. The DNA was visualized with UV-transilluminator and signals were analyzed by Image J Software version 1.52a32.

Fluorescence spectroscopy

The interaction between C10-IMD and Rv3160c was analyzed by concentration-dependent response of C10-IMD on Rv3160c tryptophan fluorescence emission measured in Hitachi F-4500 fluorescence spectrophotometer. Rv3160c emission spectra were acquired using 10 μM of protein dissolved in 1× PBS (pH 6.8) with or without adding C10-IMD and was incubated for 1 min at 37 °C in a quartz cuvette. The resulting solution was excited at 290 nm for tryptophan residue and the intrinsic fluorescence emission was scanned from 300 to 460 nm. The data from each read was then combined and plotted using the Spectragryph Software version 1.2.1333. The fluorescence quenching data have been corrected for inner filter effects. Fluorescence quenching was determined by analyzing the data by the classical Stern–Volmer equation:

F0/F=1+kqτ0Q=1+KsvQ 1

where Fo and F are the fluorescence intensities in the absence and presence of the quencher, respectively. Kq is the bimolecular quenching rate constant and Ksv is the dynamic quenching constant. Average lifetime of the protein in absence of the quencher is expressed in terms of τo whereas [Q] is the concentration of the free quencher. When small molecules interact with several comparable sites in a protein, the equilibrium between liberated and bound molecules is expressed by the equation:

logF0-F/F=logKb+n logQ 2
KD=1/Kb 3

where Kb represents binding constant for quencher-protein interaction, n is the number of binding sites per molecule of Rv3160c, KD denotes binding dissociation constant.

Circular dichroism (CD) spectroscopy

CD spectroscopy was performed with Rv3160c as described earlier34. The native secondary structure of Rv3160c was compared using far-UV range CD spectra in presence of various concentrations of C10-IMD (10 µM and 100 µM) and 86 bp rv3161c upstream DNA bait (1 µM and 10 µM). The spectra were recorded using Jasco CD spectrometer at a range of 200 to 260 nm from 10 µM of Rv3160c in optically clear buffer under the nitrogen atmosphere at 25 °C. The buffer baseline corrected spectra were processed with an average of 5 scans and presented as units of mean residue ellipticity.

Impact of isoniazid and lysozyme on bacterial growth and survival

The bactericidal/bacteriostatic properties of isoniazid and lysozyme were assayed at varying concentrations (0.002–0.064 µg/ml for INH or 3.9–125 µg/ml for lysozyme) in Sauton’s medium with 0.02% DMSO or 5 µM C10-IMD for both Mtb Erdman wild type and Δrv3161c strains as described in our previous study35.

Supplementary Information

Acknowledgements

This project has been supported under the framework of the JPIAMR – Joint Programming Initiative on Antimicrobial Resistance. C.L. is supported by the Kempe Foundation [SMK-1648] and the Åke Wilton’s Fund [FS 2.1.6-1577-17]. F.A. and C.L.S. are supported by the National Institutes of Health Grant [R01 AI134847] and the Erling-Persson Family Foundation [P20-00473]. F.A. is supported by the Swedish Research Council (JPIAMR) [2018-00969] and the Kempe Foundation [SMK-1755]. C.L.S. is supported by the Burroughs Welcome Fund Investigators in the Pathogenesis of Infectious Disease [1016717]. G.A.H. is supported by the National Science Foundation Graduate Research Fellowship [DGE-1745038] and the National Institute of General Medical Sciences Cell and Molecular Biology Training Grant [GM007067]. The personnel of the Protein Expertise Platform (PEP) at the Chemical Biological Center (KBC) at Umeå University is acknowledged for their skills and support in protein purification.

Author contributions

C.L., H.T., S.S. and S.A. designed the experiments. H.T., C.L., S.S., S.A., A.K. and I.E. performed the experiments. C.L., H.T., S.S., S.A., A.K., I.E., G.A.H., C.L.S. and F.A. analyzed the data. H.T., C.L., S.S. and S.A. wrote the main manuscript text. All authors reviewed the manuscript and the revisions.

Funding

Open Access funding provided by Umea University.

Competing interests

C.L.S. and F.A. have ownership interests in Quretech Bio AB, which licences C10-IMD. The rest of the authors have no competing interest.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Hasan Tükenmez, Email: hasan.tukenmez@umu.se.

Christer Larsson, Email: christer.larsson1975@gmail.com.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-021-81104-y.

References

  • 1.WHO. Global tuberculosis report 2019. (2019).
  • 2.Bloemberg GV, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N. Engl. J. Med. 2015;373:1986–1988. doi: 10.1056/NEJMc1505196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hoffmann H, et al. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a tibetan refugee. Am. J. Respir. Crit. Care Med. 2016;193:337–340. doi: 10.1164/rccm.201502-0372LE. [DOI] [PubMed] [Google Scholar]
  • 4.Polsfuss S, et al. Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment. Clin. Infect. Dis. 2019;69:1229–1231. doi: 10.1093/cid/ciz074. [DOI] [PubMed] [Google Scholar]
  • 5.Somoskovi A, Bruderer V, Homke R, Bloemberg GV, Bottger EC. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur. Respir. J. 2015;45:554–557. doi: 10.1183/09031936.00142914. [DOI] [PubMed] [Google Scholar]
  • 6.Flentie K, et al. Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2019;116:10510–10517. doi: 10.1073/pnas.1818009116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sukheja P, et al. A novel small-molecule inhibitor of the Mycobacterium tuberculosis demethylmenaquinone methyltransferase meng is bactericidal to both growing and nutritionally deprived persister cells. mBio. 2017 doi: 10.1128/mBio.02022-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Vilcheze C, et al. Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2017;114:4495–4500. doi: 10.1073/pnas.1704376114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Karp PD, et al. The BioCyc collection of microbial genomes and metabolic pathways. Brief Bioinform. 2019;20:1085–1093. doi: 10.1093/bib/bbx085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Romero PR, Karp PD. Using functional and organizational information to improve genome-wide computational prediction of transcription units on pathway-genome databases. Bioinformatics. 2004;20:709–717. doi: 10.1093/bioinformatics/btg471. [DOI] [PubMed] [Google Scholar]
  • 11.Betts JC, et al. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2003;47:2903–2913. doi: 10.1128/aac.47.9.2903-2913.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Parikh SL, Xiao G, Tonge PJ. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry. 2000;39:7645–7650. doi: 10.1021/bi0008940. [DOI] [PubMed] [Google Scholar]
  • 13.Balhana RJ, Singla A, Sikder MH, Withers M, Kendall SL. Global analyses of TetR family transcriptional regulators in mycobacteria indicates conservation across species and diversity in regulated functions. BMC Genom. 2015;16:479. doi: 10.1186/s12864-015-1696-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Jeon AB, et al. 2-aminoimidazoles potentiate ss-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ss-lactamase secretion and increasing cell envelope permeability. PLoS ONE. 2017;12:e0180925. doi: 10.1371/journal.pone.0180925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Waddell SJ, et al. The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds. Tuberculosis (Edinb) 2004;84:263–274. doi: 10.1016/j.tube.2003.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Dutta NK, Mazumdar K, Dastidar SG, Karakousis PC, Amaral L. New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective. Recent Pat Antiinfect. Drug Discov. 2011;6:128–138. doi: 10.2174/157489111796064597. [DOI] [PubMed] [Google Scholar]
  • 17.Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS ONE. 2010;5:e10069. doi: 10.1371/journal.pone.0010069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Aguilar-Ayala DA, et al. The transcriptome of Mycobacterium tuberculosis in a lipid-rich dormancy model through RNAseq analysis. Sci. Rep. 2017;7:17665. doi: 10.1038/s41598-017-17751-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Boshoff HI, et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 2004;279:40174–40184. doi: 10.1074/jbc.M406796200. [DOI] [PubMed] [Google Scholar]
  • 20.Cortes T, et al. Genome-wide mapping of transcriptional start sites defines an extensive leaderless transcriptome in Mycobacterium tuberculosis. Cell. Rep. 2013;5:1121–1131. doi: 10.1016/j.celrep.2013.10.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Samworth CM, Degli Esposti M, Lenaz G. Quenching of the intrinsic tryptophan fluorescence of mitochondrial ubiquinol–cytochrome-c reductase by the binding of ubiquinone. Eur. J. Biochem. 1988;171:81–86. doi: 10.1111/j.1432-1033.1988.tb13761.x. [DOI] [PubMed] [Google Scholar]
  • 22.Hinrichs W, et al. Structure of the Tet repressor-tetracycline complex and regulation of antibiotic resistance. Science. 1994;264:418–420. doi: 10.1126/science.8153629. [DOI] [PubMed] [Google Scholar]
  • 23.Kisker C, Hinrichs W, Tovar K, Hillen W, Saenger W. The complex formed between Tet repressor and tetracycline-Mg2+ reveals mechanism of antibiotic resistance. J. Mol. Biol. 1995;247:260–280. doi: 10.1006/jmbi.1994.0138. [DOI] [PubMed] [Google Scholar]
  • 24.Orth P, et al. Conformational changes of the Tet repressor induced by tetracycline trapping. J. Mol. Biol. 1998;279:439–447. doi: 10.1006/jmbi.1998.1775. [DOI] [PubMed] [Google Scholar]
  • 25.Orth P, Schnappinger D, Hillen W, Saenger W, Hinrichs W. Structural basis of gene regulation by the tetracycline inducible Tet repressor–operator system. Nat. Struct. Biol. 2000;7:215–219. doi: 10.1038/73324. [DOI] [PubMed] [Google Scholar]
  • 26.Berens C, Hillen W. Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes. Eur. J. Biochem. 2003;270:3109–3121. doi: 10.1046/j.1432-1033.2003.03694.x. [DOI] [PubMed] [Google Scholar]
  • 27.Saenger W, Orth P, Kisker C, Hillen W, Hinrichs W. The tetracycline repressor-a paradigm for a biological switch. Angew. Chem. Int. Ed. Engl. 2000;39:2042–2052. doi: 10.1002/1521-3773(20000616)39:12&#x0003c;2042::aid-anie2042&#x0003e;3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  • 28.Gomez A, Andreu N, Ferrer-Navarro M, Yero D, Gibert I. Triclosan-induced genes Rv1686c-Rv1687c and Rv3161c are not involved in triclosan resistance in Mycobacterium tuberculosis. Sci. Rep. 2016;6:26221. doi: 10.1038/srep26221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Odingo J, et al. Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents. Bioorg. Med. Chem. 2014;22:6965–6979. doi: 10.1016/j.bmc.2014.10.007. [DOI] [PubMed] [Google Scholar]
  • 30.Rock JM, et al. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nat. Microbiol. 2017;2:16274. doi: 10.1038/nmicrobiol.2016.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 32.Rasband, W. S. ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/ (1997–2018).
  • 33.Menges, F. "Spectragryph - optical spectroscopy software", Version 1.2.9. http://www.effemm2.de/spectragryph/ (2018).
  • 34.Sarkar S, et al. Ellagic acid, a dietary polyphenol, inhibits tautomerase activity of human macrophage migration inhibitory factor and its pro-inflammatory responses in human peripheral blood mononuclear cells. J. Agric. Food Chem. 2015;63:4988–4998. doi: 10.1021/acs.jafc.5b00921. [DOI] [PubMed] [Google Scholar]
  • 35.Tukenmez H, et al. Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening. Sci. Rep. 2019;9:26. doi: 10.1038/s41598-018-37176-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES